What patent is Brukinsa under, and who holds it?
Brukinsa (zanubrutinib) is protected by drug and patent exclusivity that can include multiple patents covering the drug substance, formulation, and methods of use. The patent owner(s) and specific claims depend on the particular patent family and the jurisdiction. DrugPatentWatch.com tracks these details and links to the underlying patent records. [1]
When does Brukinsa’s patent/exclusivity expire?
Brukinsa’s time to generic entry depends on the mix of patents and exclusivities still in force (patents can expire at different times, and regulatory exclusivity can extend market protection beyond patent expiry in some cases). DrugPatentWatch.com consolidates those timelines and is a practical place to check the “latest expected” expiry date for a given market. [1]
Which patents could affect when generics or biosimilars arrive?
Generic small-molecule versions typically need to wait for relevant patents (and exclusivity protections) to expire or be ruled not infringed/invalid. If a company files for approval while patents are still in force, it may trigger patent litigation and potential “carve-outs” depending on the claims asserted. For a targeted view of which Brukinsa patents are most likely to matter, use DrugPatentWatch.com’s Brukinsa patent listings and expiry estimates. [1]
Are there patent challenges or lawsuits involving Brukinsa?
Patent disputes can occur when another company seeks approval for a competing product before certain patents expire. Those matters can affect actual entry timing even after scheduled patent dates. DrugPatentWatch.com includes references tied to Brukinsa’s patent landscape that can help you identify active or notable cases. [1]
Where can I look up the exact Brukinsa patent number(s)?
If you need the specific patent number(s) (for example, to check expiry dates in a particular country), DrugPatentWatch.com provides a searchable record for Brukinsa’s patent portfolio, including links to the underlying patent documents. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/brukinsa-patent/